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"Immune regulation: what immunodeficiency disease 
has taught us" is r evie w ed b y discuss ing three immuno-
deficiency disorders. H y pogammaglobulinemia, the firs t 
documented prima r y immunodefic iency disorder , h a s a 
w ell defined and uniform clinica l presentation w hich 
r eflects a variety of underly ing abnormalities involving 
the B cell, T cell, a nd monocyte . X-linked h y pogamma -
g lobulinemia , transient hypogammaglobulinemia of in-
fancy common va ria ble immunodeficie ncy, and their 
pathogenesis are discussed. Combined immunodefi-
c iency with a denosine deaminase (ADA) deficiency first 
led to the now a cce pted concept t hat a biochemica l ab-
normality may result in immunodefic iency . The clinical 
presentation, possible biochemical abnormalities result-
ing in the observed immunodeficiency, rela tive selectiv -
ity of the defect for the immune syste m, and potential 
a pplications of knowled ge ga ined from the s tudy of ADA 
deficiency are presented. Acquired immunode fi c ie ncy 
(AIDS) has r esul ted in the concept tha t a virus is cy to-
pathic for a specific population of T cells and that this, 
a t least in part, r esults in the immunode fici e ncy seen in 
AIDS. 
The t it le "Immune Regulation: What Immunodefi ciency Dis-
ease H as T aught Us" should be extended to include "what we 
still have to lea rn". Rather t han review immune dysregu lation 
in a la rge number of immunodeficiency disorders, I have chosen 
t hree, each of whic h has presented a unique set of questions 
and answers. Hypogammaglobul inem ia, t he first documented 
primary immunodefi ciency d isorder, has a well defined and 
decept ively uniform clinical presentation which reflects a va-
r iety of underlying abnorma lit ies involving t he B cell, T cell , 
and monocyte. T he clinical ent ity hypogammaglobulinemia has 
p rompted t he evaluation of t he di fferent iation of t he B ce ll 
in human. T he second disorder, combined immunodeficiency 
with adenosine deaminase deficiency, first led to t he now 
accepted concept t hat a biochemical abnorma li ty may resul t in 
immunodefic iency. F inally, investigation of t he pathogenes is 
of acquired immunodefi ciency disease (AIDS), has resul ted in 
t he concept t hat a virus, human T-cell leukemia virus (HTLV 
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Abbreviat ions: 
ADA: adenosine dea minase 
AIDS: acquired immunodeficiency disease 
ARV: AIDS- related virus 
AT P: adenosine t riphosphate 
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dAT P: deoxy-ATP 
EBV: Epstein -Ba rr virus 
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PNP: purine nucleoside phosp horylase 
P WM: pokewood mi togen 
SCID: severe co mbined immunodeficiency disease 
SSF: soluble suppressor factors 
III) is cytopathic for a specific population of T cells and t hat 
t his, at least in part, results in t he immunodeficiency seen 111 
AIDS. 
H YPOGAMMAGLOBULINEMIA 
In 1952 Colonel 0 . Bruton [1] described t he en tity of con-
geni tal hypogammaglobulinemia in a young boy with severe 
bacteria l infections. Subsequent ly, reports of hypogammaglob-
ulinemia acquired in adolescence or adult hood appeared [2], 
now termed common variable immunodeficiency (CVI). T ran -
sient hypogammaglobulinemia of in fa ncy was defined [3]. In 
each fo rm, total serum IgG, IgM, and IgA is less t han 250 mg/ 
dl. Cell -mediated immunity is intact as reflected by total nu m-
bers of T cells and T-cell response to mitogens. Recurrent 
infec tion wit h polysaccharide-coated organisms such as He-
mophilus influenza may resul t in pneumonia, sinusitis, and 
otit is med ia. Chronic diarrhea and malabsorption are fre-
quent ly obse rved. 
Normal maturation of B cells in human involves (1) presence 
of a la rge pre-B cell with cytoplasmic IgM; (2 ) progressive 
decrease in size of t he cell with acquisit ion of cell surface 
receptors fo r E pstein-Barr virus (EBV), C3 components and 
the Fe port ion of IgG; (3 ) acquisit ion of surface IgM and IgD 
followed by IgG; (4) final diffe rent iation to an immunoglobulin 
secreting cell following interaction wi th specifi c ant igen pro-
cessed by monocytes and with T -helper cells. For t he fo llowing 
discussion , an activated B cell is defined by immunoglobulin 
sec retion, its principle d ifferent iated function and by division , 
measured by radiolabeled t hymidine uptake. In a typical im-
mune response , division p recedes diffe rentiation to the secre-
tory phase; division probably requires T-cell secreted B-cell 
growt h facto r. T he immune system's most well defined secre-
tory cell , t he plasma cell , does not divide; different iation to a 
plasma cell requires t he T -cell secreted B -cell di ffe rent iation 
facto r. (A defect at any stage of B-cell maturation may resul t 
in t he ab normal secretion of immunoglobulin and in hypogam-
maglobulinemia.) 
Congent ial hypogammaglobulinemia is characteri zed by t he 
absence of circulating small B lymphocytes bearing surface 
immunoglobul in or C3 receptors (4]. Cellular immunity is nor -
mal. However, pre-B cells have been demonstrated in t he bone 
marrow of a subgroup of t hese patien ts. T he bone marrow-
derived cells may be tra nsformed by EBV and long-term cell 
lines established. The cell lines do not always contain cells with 
surface immunoglobulin nor do t hey secrete immunoglobulin , 
however receptors fo r EBV are present [5 ]. This find ing sug-
gests t hat alt hough some patients have absent B-cell precur-
sors, others manifest conge nital hypogammaglobulinemia from 
a fa ilure of diffe rent iation of normal early precursor cell s. 
In cont rast to t he above situation, in tra nsient hypogam ma-
globulinemia of infa ncy, diffe rent iated B cells are present in 
normal numbers, but are not provided with T -cell help. Quan-
titative serum IgG in t he full term neonate is equal to or greater 
than t hat in t he mother, reflecting active tra nsport ac ross the 
placenta. T he leve l of t ransplacentally acquired IgG fa lls rap-
idly during t he first 3-4 months of postnatal life. Immunoglob-
ulin synthesis begins immediately after birt h, in response to 
colonization of t he gastrointest inal t ract, in fections, and other 
ant igenic stimulation; IgG synthesis is well established by 6 
months of li fe. This combination of events resul ts in a physio -
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logical hypogammaglobulinemia normally presen t from 4- 6 
months of life and ofte n associated with increased infection. In 
t ransient hypogammaglobulinemia of infancy, a delay in IgG 
production resul ts in a n extended period of hypogammaglobu -
linem ia, usua ll y resolving by 30- 40 mont hs of age. 
Infants with prolonged t ra nsient hypogammaglobulinemia 
have normal numbers of circu lating B cells with surface im-
munoglobulin which will synt hesize immunoglobulin when 
stimulated with EBV. H owever, t he cells synthesize dec reased 
amounts of immunoglobulin in response to pokeweed mitogen 
(PWM), aT -cell dependent B-cell activator. Further, t hey have 
decreased numbers of and function ofT-helper cell s for age 
wh ich normalize as their se rum IgG increases. Thus, t hi s form 
of hypogammaglobulinemia appea rs to reflect a transient defi -
ciency of helper T cells rather than a n abnorma lity of B cell s 
[6). 
T he etiology of the acquired form of hypogammaglobulinemia 
(CVI) is complex. Patients wit h CVI have low serum levels of 
IgM, IgG, and lgA, but nearly normal numbers of periphera l 
blood B cell s with surface immunoglobulin . Among t hese pa-
tients, some have circulat ing B cells with IgM/ IgD and no IgG; 
others have increased numbers of surface JgG-pos it ive cells a nd 
a t hird gro.up has normal percentages [7]. In a study by Saiki 
et a l [8], a portion of t he patients had an intrinsic B-cell defect 
with no proliferation/division in response to B-cell mitogens. 
In a second group, proliferation/division was normal in re-
sponse to pure B-ce ll mitogens, but cell differentiation did not 
progress to a ll ow t he secretion of immunoglobulin . In a fin al 
group, B cells proliferated normally to mitogens, but differen-
tiated only to lgM-secreting cells and not to lgG- or IgA-
secreting ce ll s. In t his particu lar study, B lymphocytes were 
isolated from severa l patients wit hin each group and were 
assessed fo r t he ab ili ty ofT ce lls obta ined from normal individ-
uals or forT-cell rep lacing facto rs to enhance B-cell differen-
t iat ion; none occu rred. Likewise, t he removal of patient T cells 
did not resu lt in normal B-ce ll proliferation. The B-cell defect 
in these patients does not appear to be explai ned by a T -cell 
defect. 
However, T-cell defects have been demonstrated in other 
patients with CVI. Tn 1972, Dr. Waldmann and associates 
reported t hat a subgroup of patients with CVI have increased 
functional T-suppressor cells [9). These patients' lymphocytes 
were capable of suppressing immunoglobulin production by 
lymphocytes from normal individua ls in response to a n appro-
priate stimulus, PWM. Numerous studies have verified this 
initia l report and suggested an additi onal defect, a n absence of 
helper T cell s in some patients. 
More recently, factors produced by T cells a nd responsible 
for t he activation a nd differentiation of B cells have been 
defined, namely B-cell growth factor a nd B-cell differentiation 
factor. Although specific defects of B-cell factors have not yet 
been identified in patients with CVI , further work in th is a rea 
may define t he basis of t he T -ce ll help required fo r t he prolif-
eration a nd differentiation of B cells to functional immuno-
globulin secreting cell s. T-cell help may be abnorma l because 
of defective production ofT-cell factors. Inte rleukin 2 (IL-2) 
produced by T cell s a nd necessary for ant ibody production but 
not implicated in B-cell differentiation, was abse nt in one 
patient wi t h CVI [10] . 
T-cell regulatory function itself depends to a large extent on 
t he modulatory action of macrophages which process ant igen 
and present it to T cells in conjunction with Ia antigen ex-
pressed on t heir surface. Mac rophage T cell interactions have 
been shown to be abnormal in 8 of 9 patients wit h CVI. It is 
possible t hat t his defect may be related to still another cell 
product, interleukin 1, produced by macrophages and necessary 
for t he stimu lation ofT -cell help [11). 
Hypogammaglobu linemia, whether diagnosed in in fa ncy or 
adu lt hood, presents with a common clinica l picture. Cell -me-
diated immunity as assessed by total numbers of T cell s and 
T -ce ll response to mitogens is ge nerally norma l or only s lightly 
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depressed. Primary B-ce ll ab norma li t ies had been defined at 
different leve ls in patients with different forms of hypogam-
maglobulinemia. Infants with congenital hypogammaglobuli-
nemia generally have decreased numbers of mature B cells with 
surface immunoglobulin but may have early B cells with recep-
tors for EBV. Patients wit h CVI most commonly have normal 
numbers of circulating B-cells defined by surface immunoglob-
ulin but a defect in either the proliferat ive or t he differentiation 
step of B-cell maturation. T -cell abnormalities have been de-
fined in a ll clinical groups. Increased T-cell suppression is 
present in approximately 50% of pat ients with CVI. Ot hers 
with CVI have decreased T-cell help as do patients with pro-
longed transient hypogammaglobulinemia of infancy. A s ingle 
patient with CVI has been defined with absent IL-2; other T-
cell derived B-ce ll factors have not been assessed in patients 
with hypogammaglobulinemia. In addition, macrophage ab nor-
malities appea r commonly in patients with CVI. The produc-
t ion of immunoglobulin by a different iated nondividing B cell 
relies on the presence of a pre-B cell a nd its orderly matu ration; 
in addition, T cell and mac rophage help provided both by cell 
interaction and by the release of appropriate factors are nec-
essary for the secretion of immunoglobu lin by a normally 
differentiated plasma cell. Defects at any of t hese levels may 
lead to hypogammaglobu linemia. 
COMBINED IMMUNODEFICIENCY WITH ADENOSINE 
DEAMINASE DEFICIENCY 
In 1972, Giblett et al desc ribed the first association between 
T- and B-cell immunodeficiency and enzyme defi ciency in two 
female children with severe combined immunodeficiency dis-
ease (SCID). Both children lacked an enzyme in t he purine 
salvage pathway, adenosine deaminase (ADA), had severely 
impaired cellular immunity, lymp hopenia, and a variable degree 
of hypogammaglobulinemia [12]. A subsequent review of 22 
children with documented SCID and kn own ADA status re-
vealed t hat 13 were ADA deficient [13], t hus establishing the 
association, if not the causative nature, of the immunodefi-
ciency a nd enzyme defect. Since t he initia l discovery of ADA 
defici ency, greater than 25 fami lies with ADA deficiency and 
immunodeficiency have been ca refully desc ribed in t he li tera-
ture (reviewed by H irschhorn a nd Ma rt in , 1978 [1 4)). A defi-
ciency of purine nucleoside phosphorylase (PNP) was first 
desc ribed in 1975 by Giblett et a] [15] in assoc iation with T-
cell deficiency and relatively prese rved B-cell funct ion. This 
second association between absence of an enzyme in the purine 
salvage pathway and SCID supported a causative affect. 
ADA deficiency is inherited in an autosoma l recessive man -
ner [16) . The majority of infected infa nts are seen usua lly 
wi t hin the first few months of life with multiple recurring 
infections and fai lu re to t hrive. The infections involve the 
respiratory t ract, the skin , and t he gastrointestinal system a nd 
are caused by a variety of organisms including fungi, protozoa, 
viruses, a nd bacteria. Mucocuta neous candidiasis is a common 
feature and overwhelming infections from Pneumocystis carinii 
and varicella zoster have been reported. Without t herapy, most 
infants die within t he first year of life . The clinical manifesta-
t ions of t his form of ADA deficiency result from significant 
abnormali ties ofT-cell immunity and moderate abnormalities 
of B-cell immunity. Severe lymphopenia is often present . De-
layed hypersensitivity skin test responses a re absent a nd in 
vitro lymphocyte responses to the mitogen phytohemagglutinin 
(PHA) and to a lloant igens (mixed lymp hocyte cul ture) are 
depressed. Quantitative immunoglobu lins are low to absent and 
evidence for a specific antibody response to antigen is variably 
absent. The remainder of the group (approximately 10%) with 
ADA deficiency have a delayed clinical presentation. As t he 
infants become older, susceptibility to infections increases. In 
t his group , T -cell function is more seve rely affected t han B-
cell immuni ty [17]. 
Drs. Hirschhorn and Martin [14] posed 4 major questions 
concerning t he associat ion between enzyme defects a nd im-
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munodeficiency diseases. These questions were: "1. What is t he 
metabolic mec hanism(s) of t he pathogenicity? 2. What is t he 
basis of t he rema rkab le organ systems specificity? 3. What are 
t he pathogenic relationships if any, between the genetically 
d istinct di seases a ·sociated wi t h enzyme defects? 4. Do any of 
the above provide important insights into t he basic mechani sms 
by which t he immune system functions or means by which it 
may be manipu lated? " 
As basic laboratory wo rk on ADA deficiency has resulted in 
a more complete understanding of t he pathogenesis of t his 
disease t han work concerning PNP defic iency, I wi ll confine 
my comments concern ing pathogenesis to t he first di so rder. 
ADA cata lyzes t he conve rsion and deamination of ade nosine 
and deoxyadenosine to inosine and deoxyinosine in t he puri ne 
(deoxy) ribonucleoside catabolic pathway. Although there are 
severa l molecul a r forms of ADA in huma n t issue, ert hyrocytes 
as we ll as lymphocytes contai n primarily t he low molecular 
we ight of ADA. It appears that t he t issue, red cell , and lympho-
cyte form of ADA a re deficient in patients with im munodefi-
ciency and ADA defi ciency, suggesting t hat t hey are all prod-
ucts of t he same ge ne. The ge ne fo r ADA is located on chro-
mosome 20 in t he human. There is a s ingle locus with 2 a lleles 
[17]. An ea rly t heo ry that the immunodeficiency found in ADA 
deficien t patients resul ted from a linkage between the struc-
tural ge ne for ADA and the HLA locus was eli minated foll owing 
the assignment of disc rete structura l genes for ADA, PNP, and 
t he HLA locus on 3 separate human chromosomes. 
It seemed most li ke ly t hat t he pathogenesis of the ab normal 
immune system in ADA defic iency foll owed genera l principles 
for in herited metaboli c diso rders. T hat is , t he immunodefi -
ciency resu lts from (a) a deficiency of t he product of t he absent 
enzyme; (b) t he accum ulation of a toxic substrate; or (c) t he 
accumulation of a tox ic metabo li te of a substrate of t he abse nt 
en zyme. 
The ini t ia l studies of purine metaboli sm in ADA defici ent 
patien ts suggested t hat adenosine was t he most li kely candidate 
to produce lymphocyte tox icity because it was elevated in the 
plasma of a n ADA -defi cient child [18] and , in a se ries of studies, 
was found to he tox ic to normal lymphoid cell s in the presence 
of an ADA inhibitor in vitro [19,20]. T hree suggestions were 
made conce rning possible mechanisms of lymphocyte tox icity 
fo r ade nos ine or adenosine metabo li tes. First, t he incubation 
of human perip hera l blood lymphocytes with different concen-
trations of adenos ine resul ted in an increase in in t racellula r 
cycl ic AMP; dipyridamole, a drug known to block adenosine 
uptake, d id not bloc k t he effect of ade nosine on t he lymphocyte 
cAMP leve l, suggesting t hat adenosi ne was active on an extra 
cellular s ite , presumably a ce ll surface receptor site [21,22]. 
Intracellula r cyc li c AMP is a known immunosuppress ive age nt . 
T he increased se ru m adenosine in patients with ADA deficiency 
could saturate ce ll su rface ade nosine receptors, increase intra-
cellu lar cycl ic AMP through a receptor n}8chanism, and pro-
duce immunodeficiency. Secondly, it was hypothesized t hat 
adenosine pyrim id ine nucleotides inhibi t t he growt h of cul tured 
cell s by pyrimidine sta rvation which are necessa ry for DNA 
replication [23]. 
These studies were ca rri ed out on two estab li shed cell lines 
of lymp hoid ori gin and, t he end point was dimini shed growth 
in t he presence of adenos ine. However, t his specific mechanism 
is no longe r accepted as t he primary cause of immunodeficiency 
in ADA-deficient ce lls , because t he addit ion of a pyrimidi ne, 
uridine, to ADA defic ient periphera l blood mo nonuclea r ce ll s 
did not restore normal growth. Further, a mutan t cell line was 
developed lack ing ade nosine kinase, presumably necessa ry fo r 
pyrimidine starvation; this ce ll line was also susceptible [24]. 
The th ird explanation put forth for t he tox icity of adenos ine 
to lymphocytes in patients with ADA de fi ciency was t hat 
exogenous adenosine resul ted in t he in tracellula r accumulatio n 
of S-adenosy l-homocystine, wh ich in turn acts as an inhibitor 
of methy lation reactions. Both in normal perip hera l blood 
mononuclea r ce ll s 125] and in a human lymphoblasto id line 
[26] adenosine inhibi ts t he uptake of radiolabeled thymidine 
and leucine, presumably by inhibiting methylation. Methyla-
t ion reactions are necessary fo r t he production of DNA. The 
inhibition of methylation by S-adensyl homocystine accounts 
for t he observed uridine-resistant adenosine toxicity in human 
lymphoblastoid lines; t h is mechan ism is fe lt by many investi-
gators to at least contribute to t he immunodeficiency in ADA 
deficient patients. 
Subsequently, attent ion tu rned to body fluids and tissues 
obtained either fresh or cul tured from patients with ADA 
deficiency. Pol mar eta] first documented a ten-fold increase in 
lymphocyte adenosine triphosphate (ATP) in an untreated 
patient. ATP levels returned to normal after the infusion of 
irradiated erythrocytes conta ining ADA; immune function a lso 
norma li zed [27]. It was clear that t he addi tion of ADA activity 
eit her in vivo (by erythrocyte tra nsfusions) or in vitro allowed 
for t he part ia l reconstitution of cellular immune fu nction . 
T herefo re, it appeared t hat ADA was removing some poten-
tia lly tox ic substrate(s). However, that tox in did not appear to 
be exclusively adenosine. Further studies revea led t hat eryth-
rocytes of ADA deficient, immunodeficient patients had in -
creased concentrations of deoxyadenosine and deoxy-ATP 
(dATP) (28]. These increased levels often return to normal 
fo llowing treatment, and dA TP appear to co rrelate better with 
the reconstit ut ion of immune funct ion in patients t han ATP 
leve ls. Therefo re, it was postulated t hat t he potential "toxin" 
was deoxyadenos ine rather than adenosine. 
Studies to substant iate t he t heory t hat ADA defic iency and 
immunodeficiency resul ts in part from increased deoxyadeno-
sine and increased dATP rather than increased adenosine and 
ATP include t he fo llowi ng. Peripheral blood mononuclear cells 
obta ined from ADA defic ient, immunodeficient patients were 
sensit ive to 100- 1,000 fo ld lower concentrations of deoxyaden-
os ine t han were peripheral blood mononuclear cells obta ined 
from normal individuals. This was in contrast to t he previous 
experience utili zing adenosine. T he mechan ism of deoxyaden-
osine toxic ity remained unknown. Deoxy-ATP is an inhibitor 
of t he ribonucleotide reductase activities responsible for t he 
production of deoxyribonuc leotides and thus, ul timately, for 
t he production of the substrates necessary for DNA synthesis . 
T he t heory t hat increased levels of dATP resul t in immuno-
defi ciency via inhibition of ribonucleotide reductase is sup-
ported by a ce ll model system in which micromolar concentra-
tions of deoxyadenosine result in a marked increase in intra-
ce llular dA TP and a depletion of t he deoxynucleotides, espe-
cia lly deoxycytidine. In t his particu la r system, t he tox icity of 
deoxyadenosi ne has been shown to be completely independent 
of cycl ic AMP mediated effects [29,30]. One wou ld predict t hat 
if t he model is correct, the ADA induced immunodefic iency in 
man could be repaired in vivo by the infusion of deoxycytidine. 
However in two infants with ADA deficiency and severe com-
bined im:nunodeficiency, t he infusion over long periods of time 
of large amoun ts of deoxycytidine, which accumulated intra-
cellula rly, did not resul t in clinical improvement or reconsti-
tution of cellular immunity [31]. There are at least 3 explana-
t ions for t hese fi ndings: (1) deoxycytidine did not reac h the 
potential ta rget cell s; (2) t he target cells were no longer present 
in t he infants; or (3) the major mechan ism for t he toxicity in 
ADA defici ency is not limi t ing amoun ts of dCTP resul ting from 
the inh ibition of ri bonucleotide reductase deficiency. In support 
of t his latter possibi lity, an effort to increase immunodeficiency 
in an infant with ADA deficiency, in order to prepare the infant 
for bone marrow t ransp lantation, by infusing large amounts of 
the presumed toxic metaboli te deoxyadenosine, resulted in a 
marked increase in intracellular dATP levels. However, no 
dimunition of immune response measured either by lymphocyte 
response to lectins or to allogeneic ce lls was observed (M.J. 
Cowan, personal communication). 
Therefore, a s ingle explanation for t he immunodeficiency 
observed in children with ADA deficiency is not ava ilable. Most 
likely, ADA defi ciency resul ts in a combi nation of defects, 
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including increased levels of deoxyadenosine and dA TP with 
ribonucleotide reductase deficiency, increased intracellular 
cyclic AMP resulting from saturation of cell surface adenosine 
receptors, and inhibition of essential methylation reactions by 
S-adenosyl homocystine. 
An additional question, remaining to be answered in infants 
with ADA and related enzyme deficiencies, is an explanation 
for the specific susceptibility of the immune system and of its 
components. There are at least 3 explanations for th is specific 
susceptibility. First, lymphocytes are rapidly proliferating ce lls, 
requiring large amounts of DNA. Any defect resulting in ab-
normal DNA format ion would favor destruction of lymphocytes 
over other cells. Second, the concentration of ADA is high in 
peripheral lymphoid t issue, especially tissue correlating with 
T-cell activity [32]. lt is higher in cortical thymocytes than in 
medullary thymocytes [33], suggesting a role for ADA in the 
differentiation of competent T ce ll s. In cell models, ADA defi-
ciency appears to produce increased toxicity via increased 
amounts of deoxyadenosine during the early stages of T -cell 
development. Finally, deoxyadenosine is a free ly diffusible com-
pound which is phosphorylated intracellularly by a specific 
kinase. The spec ific kinase activity is largely localized to lymph-
oid cells, allowing only these cells to phosphorylate and there-
fore to t rap the diffusible deoxyadenosine [34). In this cell 
model, a ll lymphocytes contain the specific kinase for deoxy-
adenosine and appear equally susceptible to ADA deficiency. 
However, in infants with ADA deficiency, the T -cell system is 
more severely affected than the B-cell system. Numerous in-
vestigators have attempted to explain the "protection" of B 
cells to ADA deficiency. T helper cell activity and the ability 
of B cells to differentiate to the antibody secreting stage are 
differentially protected in vitro when incubated with ADA 
inhibitors and deoxyadenosine; T suppressor activity is mark-
edly affected in the studies [35). In a single study, normal 
peripheral blood B cell s appeared to degrade deoxynucleotide; 
t hus, B cells did not accumulate toxic dATP [36]. lt is hypoth-
es ised that the ecto-5' nucleotidase, present on the surface of 
B cells in larger concentrations than on the surface of T cells, 
is responsible for the intracell ular degradation of the deoxyn -
ucleotides. In th is model, dATP would not accumulate intra-
cellulary, ribonucleotide reductase would not b~ inhibited and 
DNA synthesis would procede more normally 111 B cells than 
in T cells. 
It is clear t hat understanding the mechanism(s) for the 
immunodeficiency found in ADA deficient patients will help to 
define the normal immune response. Further, understanding 
the differential effects of accumulated metabolites on B and T 
lymp hocytes may help to define their unique characte ristics. It 
is already obvious that the recognition of the immunologic 
disorder associated with ADA deficiency will provide a means 
of manipu lating the normal immune system. The use of phar-
macologic agents with adenosine deaminase inhibitor activity 
may we ll add to the treatments avai lable for leukemias. Al -
though early trials with 2' deoxycoformycin as an adjuvant 
treatment of lymphoid malignancies have been disappointing 
[37,38], fu ture studies utilizing a similar approach may yield 
new therapeutic modalities. 
ACQUIRED IMMUNODEFI CIENCY SYNDROME 
During the past four years, first in the United States and 
subsequently in other parts of the world, investigators have 
described an acquired immunodeficiency syndrome (AIDS). 
This syndrome is characterized by lymphopenia with a de -
creased percentage of helper T -lymphocytes and an increased 
percentage of suppresso r T -lymphocytes [39- 46). AIDS has 
occurred primarily in homosexuals with multiple partners, i.v . 
drug users, and Haitians, but has been reported in hemophiliacs 
a nd in both infants and adults receiving blood transfusions 
from an individual with documented AIDS [47]. The syndrome 
appears to have a latency period between 6 months to 2 years 
and may be preceded by a lymphadenopathy syndrome (LAS) . 
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The risk of Kaposi's sarcoma in this population is at least 100-
fold greater than in the general population. An additional 
association is that of opportunistic infections from a variety of 
microbial agents, including pneumocystis carinii. The mortality 
and apparent irreversibility of AIDS in patients with Kaposi 's 
sarcoma and/or opportunistic infections has encouraged inves-
tigators to define the immune status and to search for an 
underlying infectious etiology in this patient population. 
A common denominator in patients with AIDS is a profound 
selective defect in cellular immunity [48,49]. The most consist-
ently observed defect has been a depression in the ratio of T 
helper/ inducer cells (defined by OKT-4 or Leu-3 monoclonal 
antibodies) to suppressor/cytotoxic cells (defi ned by OKT-8 or 
Leu-2 monoclonal antibodies) . Recently, retrovirus termed 
AIDS-related virus (ARV), lymphadenopathy associated virus 
(LA V), or HTLV III by various investigators, has been identi-
fied in patients with AIDS. The virus has a selective tropism 
for and subsequent cytopathic effect in helper/ inducer T-lym-
phocytes, probably explaining the decreased numbers of these 
cells seen in patients with AIDS [50] . T -cell functions (defined 
by lymphocyte response to T dependent mitogen, antigens and 
alloantigens) is depressed in patients with AIDS but is most 
abnormal in patients with opportun istic infections [48,49). An 
explanation, in addition to decreased numbers ofT helper cells, 
for t he abnormal T-cell function and immunoregulation ob-
served in these patients may be the elaboration of soluble 
suppressor factors (SSF) [51,52). SSF is elaborated by AIDS or 
LAS T cells fo llowing interaction with autologous or normal 
adherent cells. SSF can inhibit T-cell response to antigen and 
PWM-induced B-cell proliferation by normal peripheral blood 
mononuclear cells. 
Antibody-mediated immunity has been described as normal 
or overactive with normal or elevated immunoglobulins in 
AIDS patients. However, primary antibody responses to anti-
gens, such as keyhole limpet hemocyanin, are severely de-
pressed [53). Evaluation of B-cell function in vitro in patients 
with AIDS has revealed the "spontaneous" polyclonal activa-
tion of B-cell lymphocytes with an increased number of cells 
secreting immunoglobulin. In the same patients, decreased 
proliferative responses to T -cell dependent B-cell mitogens, 
ref1ecting abnormal resting B cells, were reported [54) . A pos-
sible explanation for the discrepancy between the decreased 
absolute number ofT -helper cell s and the increased polyclonal 
activation of B cells is a decrease in the subset ofT -helper cells 
not normally required for help in B-cell responses with the 
preservation of t he subset required for help [55). 
All investigators' evaluations of B-cell function in AIDS 
suggest that in addition to ab!lormalities of T -cell regulation, 
a fundamental but as yet unidentified defect in B cells exist 
[54 ,55). The pathogenesis of B-cell polyclonal activation re-
mains unknown. Possible explanations include the transfor-
mation of B cel ls by cytomegalovirus (CMV), EBV or a related 
agent in addition to infection with HTL V III. Patients with 
either LAS or AIDS have serologic evidence of recurrent infec-
tion with both EBV and CMV. It is unlikely that EBV is 
functioning as a B-cell polyclonal activator in patients with 
AIDS. Following the long term culture of B-cell enriched pe-
ripheral blood mononuclear cells obtained from individuals 
with LAS, the polyclonally activated cells secreted abnormally 
increased amounts of lgG. Cells infected with EBV secrete 
primarily IgM. Epstein-Barr nuclear antigen could not be de-
tected in the cells at the termination of culture [56]. This 
finding, in addition to the cellular secretion of IgG in preference 
to lgM effectively excludes EBV as an in vivo polyclonal 
activator. CMV has also been reported as a polyclonal activator 
of B lymphocytes and has not been systematically investigated 
in B cells of patients with AIDS. 
During the past four years it has been established that only 
a small subpopulation of men with LAS progress to develop 
AIDS. However, most men with LAS have elevated antibody 
titers to CMV, EBV and, most recently LA V /HTL V III/ ARV 
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ret rovirus. Therefore, a lthough infectivity of T -helper cell s wi t h 
LA V / HTL V III / ARV nicely explains t he observation of de-
creased T-he lper ce lls in m en both with LAS a nd with AIDS, 
it alone is not a co mplete expla nation for t he development of 
AIDS. Infectivi ty with t he retrovirus may result in AIDS in a 
yet not identified group of pat ients with a spec ific ge netic 
background. Alte rnatively, AIDS may resul t fro m a "doubl e 
hit" mechanis m ; t hat is, infection with a retrovirus followed by 
or s imulta neous wi t h infectio n wi t h a virus s imila r to C MV 1 
EBV, may induce t he polyclon a l activation of B ly mphocytes 
and other immune a bnorma li t ies seen in AIDS. 
SUMMARY 
Abnorma l immune response a nd dysregulation is found in 
p atients with a variety of primary or secondary immunodefi-
c ien cy diso rde rs. The three I have chosen to discuss represent 
a general overview of dys regu lation in immunodefi c iency wi t h -
out a common pathoge nesis: (hypogammaglobulinemia) , an 
e n zyme defi c iency resulting in seve re combined immunode fi-
c iency disease (adenosine dea minase defi c iency) , and t he infec-
t ion of a subpopulation ofT lymp hocytes by a cytotropic virus 
resulting in an a bnorma l immune response (acquired immu-
nodeficiency syndrome) . The pathogenesis of none of t hese 
disorders is comple te ly unde rstood. Hypogammaglobulinemia 
(con genita l, prolonged transient, common va ria ble immunode-
ficiency) may result fro m a n in t rins ic a bno rmality of B cells, 
T cells, and/or monocytes. Although the relationship between 
absent ADA a nd t he immunodefic ie ncy observed in a subpop -
ulation of infan ts with seve re co mbined immunodefic iency 
d isease is established, the exact pathogenesis of the disordered 
immune response remains unknown. Most like ly , both abnor-
mal methy la t ion a nd increased qua ntities of intrace llula r deox-
yadenos ine and dA TP resul t in t he immunode fi ciency observed. 
The recent documentation t hat a specific ret rovirus (LA VI 
HTLV Ill/ ARV) is cytotropic a nd cytopathic fo r huma n T -
helper cel ls in men with AIDS a lo ne does not provide a com-
plete ly satis fac tory explanation for t h e immunologic findings 
described in men with this syndrome. 
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